Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104


The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 20, 2019


  • Drug: ABBV-8E12
    • Solution for infusion

Arms, Groups and Cohorts

  • Experimental: ABBV-8E12
    • ABBV-8E12 administered by intravenous (IV) infusion.

Clinical Trial Outcome Measures

Primary Measures

  • Adverse Events
    • Time Frame: From first dose of study drug to 20 weeks after last dose of study drug (up to 2 years, 5 months)
    • Adverse events and serious adverse events will be monitored throughout the dosing period and for approximately 20 weeks after the last dose.

Participating in This Clinical Trial

Inclusion Criteria

  • Subject completed Study C2N-8E12-WW-104 (NCT02494024) – Subject was not eligible to enroll in Study M15-562 (NCT02985879) Exclusion Criteria:
  • Subject weighs less than 35 kg at screening – Subject has any contraindication or inability to tolerate brain MRI – Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • AbbVie
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • AbbVie Inc., Study Director, AbbVie

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.